Signs Exclusive Distributors for Greece and Caribbean Countries
Tel Aviv, Israel, March 01, 2018 -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed an exclusive distribution agreement with T-Vascular IKE Medical Supplies, in Greece, and Endo-Serv, SRL in the Caribbean, both of whom are premier suppliers of high-tech medical devices used in minimally invasive procedures. Endo-Serv markets products in the Dominican Republic, Jamaica, Aruba, Curacao, as well as Trinidad and Tobago.
Agustin Gago, EVP and Chief Commercial Officer of InspireMD, commented, "We continue to expand our commercial footprint across Europe through this latest partnership with T-Vascular IKE Medical Supplies in Greece. Our agreement with Endo-Serv also provides us with an ideal foothold across the Caribbean region. Importantly, both of these distributors have established relationships with KOLs at the leading hospitals in each of their respective markets. We believe our ability to attract the top distributors from around the world further illustrates the growing market demand for our technology.”
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.
InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS.
Forward-looking Statements
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts: InspireMD, Inc. Craig Shore Chief Financial Officer Phone: 1-888-776-6804 FREE Email: [email protected] Crescendo Communications, LLC David Waldman Phone: (212) 671-1021 Email: [email protected]


SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings
Nintendo Shares Jump as Switch 2 Sales Boost Earnings
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 



